JO3291B1 - الأجسام المضادة لـ csf-1r - Google Patents

الأجسام المضادة لـ csf-1r

Info

Publication number
JO3291B1
JO3291B1 JOP/2011/0097A JOP20110097A JO3291B1 JO 3291 B1 JO3291 B1 JO 3291B1 JO P20110097 A JOP20110097 A JO P20110097A JO 3291 B1 JO3291 B1 JO 3291B1
Authority
JO
Jordan
Prior art keywords
csf
antibodies
antibodies against
against csf
internalizing
Prior art date
Application number
JOP/2011/0097A
Other languages
English (en)
Inventor
Francoise Doody Jacqueline
Li Yanxia
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Application granted granted Critical
Publication of JO3291B1 publication Critical patent/JO3291B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

يقدم الاختراع جسمًا مضادًا بشريًا يرتبط بـ CSF-1R بشري بألفة عالية. إن للأجسام المضادة وفقًا للاختراع الحالي فوائد هامة مقارنة بالأجسام المضادة المعروفة في المجال إذ أنها متعددة الوظائف وتتمثل في: تثبيط إشارات CSF-1R، امتصاص وحث انحلال CSF-1R وتحفيز ADCC في الخلية المشتملة على الأورام، الخلايا الملتهمة الكبيرة والخلايا أحادية النواة. وقد اتضح أيضًا أنها تعد فعالة في علاج اللوكيميا، سرطان الثدي وبطانة الرحم والبروستاتا وذلك بمفردها أو بالاشتراك مع دوسيتاكسيل، باكليتاكسيل، Herceptin® أو دوكسوروبيسين.
JOP/2011/0097A 2010-04-01 2011-03-22 الأجسام المضادة لـ csf-1r JO3291B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31989610P 2010-04-01 2010-04-01

Publications (1)

Publication Number Publication Date
JO3291B1 true JO3291B1 (ar) 2018-09-16

Family

ID=44010222

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0097A JO3291B1 (ar) 2010-04-01 2011-03-22 الأجسام المضادة لـ csf-1r

Country Status (30)

Country Link
US (1) US8263079B2 (ar)
EP (2) EP2552966B1 (ar)
JP (1) JP5767310B2 (ar)
KR (1) KR101439719B1 (ar)
CN (1) CN102834414B (ar)
AR (1) AR080698A1 (ar)
AU (1) AU2011232850B2 (ar)
BR (1) BR112012024564A2 (ar)
CA (1) CA2795081C (ar)
CY (1) CY1119324T1 (ar)
DK (1) DK2552966T3 (ar)
EA (1) EA021600B1 (ar)
ES (1) ES2640909T3 (ar)
HR (1) HRP20171153T1 (ar)
HU (1) HUE036379T2 (ar)
IL (1) IL222222A (ar)
JO (1) JO3291B1 (ar)
LT (1) LT2552966T (ar)
ME (1) ME02806B (ar)
MX (1) MX2012011234A (ar)
NZ (1) NZ602621A (ar)
PL (1) PL2552966T3 (ar)
PT (1) PT2552966T (ar)
RS (1) RS56219B1 (ar)
SG (1) SG183829A1 (ar)
SI (1) SI2552966T1 (ar)
TW (1) TWI402078B (ar)
UA (1) UA111818C2 (ar)
WO (1) WO2011123381A1 (ar)
ZA (1) ZA201206926B (ar)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2949670T (pt) 2009-12-10 2019-05-20 Hoffmann La Roche Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
WO2011107553A1 (en) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CN107011438B (zh) 2010-05-04 2020-11-20 戊瑞治疗有限公司 结合csf1r的抗体
US9161968B2 (en) * 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
CA2861122A1 (en) * 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
NZ720949A (en) 2013-12-09 2019-03-29 Univ Leland Stanford Junior Methods and compositions for treating aging-associated conditions
KR102000224B1 (ko) * 2014-02-03 2019-07-16 전대연 스마트 이메일 관리방법
JP6964410B2 (ja) 2014-06-23 2021-11-10 ファイヴ プライム セラピューティクス インク コロニー刺激因子１受容体（ｃｓｆ１ｒ）に結合する抗体で疾患を治療する方法
LT3212670T (lt) 2014-10-29 2021-02-10 Five Prime Therapeutics, Inc. Kombinuotasis vėžio gydymas
ES2843586T3 (es) 2014-12-22 2021-07-19 Five Prime Therapeutics Inc Anticuerpos dirigidos contra CSF1R para tratar la SVNP
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
CN107660152B (zh) 2015-05-27 2021-11-05 Ucb生物制药私人有限公司 用于治疗神经系统疾病的方法
SI3307296T1 (sl) 2015-06-15 2022-04-29 The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel TIMP2 za uporabo pri zdravljenju s starostjo povezanih stanj
JP6621252B2 (ja) * 2015-06-17 2019-12-18 国立大学法人北海道大学 治療耐性がんに対する治療耐性低減剤
EP3108897A1 (en) * 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
MX2017016651A (es) * 2015-06-24 2018-05-14 Hoffmann La Roche Anticuerpos contra csf-1r humano para su uso en la induccion de linfocitosis en linfomas o leucemias.
EP3973988A1 (en) * 2015-11-04 2022-03-30 Duke University Combination therapy of immunotoxin and checkpoint inhibitor
WO2017085566A1 (en) * 2015-11-20 2017-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increase/induction of immune responses
JP2018531278A (ja) * 2015-11-24 2018-10-25 イーライ リリー アンド カンパニー 癌のための併用療法
MA44309A (fr) * 2015-11-25 2018-10-03 Nogra Pharma Ltd Oligonucléotides antisens il-34 et leurs procédés d'utilisation
ES2900302T3 (es) 2016-04-28 2022-03-16 Alkahest Inc Fracciones de plasma como terapia para el crecimiento y la progresión del tumor
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
TW201825519A (zh) 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
EP3558360A1 (en) * 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
WO2018144334A1 (en) 2017-02-02 2018-08-09 Imclone Llc Dosing regimen for anti-csf-1r antibody
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
CN110709422B (zh) 2017-04-19 2023-12-26 马伦戈治疗公司 多特异性分子及其用途
DK3615057T3 (da) 2017-04-26 2024-01-02 Alkahest Inc Doseringsskema til behandling af kognitive svækkelser med blodplasmaprodukter
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
EP3624848A1 (en) 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Combination therapies
KR20240138135A (ko) 2017-08-25 2024-09-20 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 그의 사용 방법
KR20200051024A (ko) 2017-09-13 2020-05-12 파이브 프라임 테라퓨틱스, 인크. 췌장암에 대한 조합 항-csf1r 및 항-pd-1 항체 조합 요법
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
KR20200123170A (ko) 2018-02-21 2020-10-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 제형
GB201803226D0 (en) 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
MA52416A (fr) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
CN120590539A (zh) * 2018-03-28 2025-09-05 百时美施贵宝公司 白介素-2/白介素-2受体α融合蛋白以及使用方法
CN112566935B (zh) * 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
CN108948201B (zh) * 2018-07-18 2019-05-07 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及应用
CN108948200B (zh) * 2018-07-18 2019-05-10 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及其应用
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
EA202190183A1 (ru) 2018-07-27 2021-05-18 Алектор Ллс Антитела к siglec-5 и способы их применения
EP3856350A1 (en) 2018-09-27 2021-08-04 Marengo Therapeutics, Inc. Csf1r/ccr2 multispecific antibodies
IL282227B2 (en) 2018-10-26 2024-08-01 Alkahest Inc Use of plasma and plasma fractions to improve pain, wound healing and recovery after surgery
US12043668B2 (en) 2018-12-13 2024-07-23 Development Center For Biotechnology Anti-human CSF-1R antibody and uses thereof
WO2020178313A1 (en) * 2019-03-05 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarkers and biotargets in renal cell carcinoma
WO2020232051A1 (en) * 2019-05-15 2020-11-19 Biosion Inc. Antibody binding csf-1r and use thereof
JP2022532837A (ja) * 2019-05-24 2022-07-20 エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド 抗ｃｓｆ１ｒ抗体、ｉｌ１０融合タンパク質、及びそれらの使用
CN110499295A (zh) * 2019-09-11 2019-11-26 宝船生物医药科技(上海)有限公司 一种csf-1r报告基因细胞株及其制备方法和应用
EP4034558A1 (en) 2019-09-26 2022-08-03 Roche Diagnostics GmbH Anti-csf-1r antibody
JP7513709B2 (ja) * 2019-10-17 2024-07-09 ナショナル ヘルス リサーチ インスティテューツ 抗コハク酸モノクローナル抗体およびヒト化抗コハク酸抗体
KR102373965B1 (ko) * 2020-06-05 2022-03-15 (주)지아이이노베이션 Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
CN115806626B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用
AU2024274397A1 (en) 2023-05-17 2025-11-13 Syndax Pharmaceuticals, Inc. Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
FI895955A7 (fi) 1988-04-15 1989-12-13 Protein Design Labs Inc Il-2-reseptorispesifisiä "kimeerisiä" vasta-aineita
AU627183B2 (en) 1988-04-16 1992-08-20 Celltech Limited Method for producing recombinant dna proteins
JPH0967400A (ja) 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
CA2505994A1 (en) * 2002-11-15 2004-06-03 Chiron Corporation Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
KR100996801B1 (ko) 2005-03-08 2010-11-25 파마시아 앤드 업존 캄파니 엘엘씨 항-ＭＡｄＣＡＭ 항체 조성물
CN101802008B (zh) * 2007-08-21 2015-04-01 安美基公司 人类c-fms抗原结合蛋白
AU2009224955B2 (en) * 2008-03-14 2012-08-09 Transgene S.A. Antibody against the CSF-1 R

Also Published As

Publication number Publication date
AR080698A1 (es) 2012-05-02
ES2640909T3 (es) 2017-11-07
EP3156419A1 (en) 2017-04-19
EA021600B1 (ru) 2015-07-30
NZ602621A (en) 2014-02-28
CN102834414B (zh) 2014-10-08
HUE036379T2 (hu) 2018-07-30
KR20130001258A (ko) 2013-01-03
MX2012011234A (es) 2012-11-30
IL222222A0 (en) 2012-12-31
WO2011123381A1 (en) 2011-10-06
HRP20171153T1 (hr) 2017-10-06
JP2013529183A (ja) 2013-07-18
PL2552966T3 (pl) 2017-12-29
IL222222A (en) 2016-02-29
AU2011232850B2 (en) 2014-06-19
ZA201206926B (en) 2014-03-26
TWI402078B (zh) 2013-07-21
US20110243947A1 (en) 2011-10-06
EP2552966B1 (en) 2017-07-05
EP2552966A1 (en) 2013-02-06
CN102834414A (zh) 2012-12-19
TW201138824A (en) 2011-11-16
LT2552966T (lt) 2017-10-10
UA111818C2 (uk) 2016-06-24
ME02806B (me) 2018-01-20
CY1119324T1 (el) 2018-02-14
SG183829A1 (en) 2012-10-30
CA2795081C (en) 2017-12-05
RS56219B1 (sr) 2017-11-30
US8263079B2 (en) 2012-09-11
PT2552966T (pt) 2017-09-29
DK2552966T3 (en) 2017-08-14
CA2795081A1 (en) 2011-10-06
BR112012024564A2 (pt) 2016-11-29
EA201270732A1 (ru) 2013-01-30
SI2552966T1 (sl) 2017-08-31
JP5767310B2 (ja) 2015-08-19
AU2011232850A1 (en) 2012-09-06
KR101439719B1 (ko) 2014-09-12

Similar Documents

Publication Publication Date Title
JO3291B1 (ar) الأجسام المضادة لـ csf-1r
MY181086A (en) Anti-egfr antibodies and uses thereof
MX2020010639A (es) Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer.
WO2012009406A3 (en) Gold particles and methods of making and using the same in cancer treatment
NZ596490A (en) Monoclonal antibodies that bind GT468 for the treatment of cancer
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
MY160628A (en) Therapeutic DLL4 Binding Proteins
MX349662B (es) Anticuerpos de antigenos antitumorales y metodos de uso.
MX2013004761A (es) Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MX2015013203A (es) Conjugados de anticuerpo - farmaco.
PH12012502215A1 (en) Anti-fgfr2 antibodies
PH12013502043A1 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
MX2012001783A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona.
HK1255815A1 (zh) 治療腹膜癌的組合物和方法
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
MX2009010271A (es) Tratamiento combinado del cancer con anticuerpo anti cd20 e interleucina 18 humana.
WO2009124281A3 (en) Novel antibodies against cancer target block tumor growth, angiogenesis and metastasis
WO2011119888A3 (en) N-cadherin: target for cancer diagnosis and therapy
WO2009148896A3 (en) Anti-phospho-akt antibodies
UA100694C2 (ru) АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С CD79b, ИММУНОКОНЪЮГАТ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2012028334A3 (en) Marker for sunitinib resistance formation
TN2013000387A1 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2